EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Sepsis as a complex syndrome: Are combined biomarkers the future of diagnosis and prognosis? Clinical perspective

R Ghaderpanah, F van Beuningen, Y Lin, S H Sadrian, H M Reijneveld, H Krabbe, P Jonkheijm, H R Bouma, R T Mankowski

Immunology Letters · 2026-02 · 277 · 107072

DOI: 10.1016/j.imlet.2025.107072 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology Letters, 2026-02. Verfasst von R Ghaderpanah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Aging, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Biomarkers, Sepsis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institutes of Health, NIH National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis remains a major cause of mortality worldwide, driven by a dysregulated host response to infection that leads to life-threatening organ dysfunction. Despite advances in evidence-based medicine, early diagnosis and risk stratification remain significant challenges due to the complex, multifaceted nature of sepsis and substantial interindividual variability in clinical presentation. Current approaches relying on single biomarkers cannot provide comprehensive insights into disease progression, limiting their clinical utility in guiding timely and effective interventions. Given the limitations of current single biomarkers in capturing the complexity of sepsis, there is an urgent need for improved diagnostic approaches. While the discovery of novel biomarkers remains important, combining existing biomarkers may offer a pragmatic and effective strategy to improve diagnostic accuracy by leveraging the strengths of each to compensate for the limitations of other. In this clinical perspective, we highlight the potential of such combined biomarker strategies to enhance diagnostic accuracy, support identification of the infection source, and improve prognostic assessment across the clinical course and into long-term outcomes. We provide examples of key biomarkers and their synergistic potential, emphasizing the need for advanced analytical methods such as machine learning and multi-omics integration to enhance predictive accuracy. Shifting toward multi-component biomarker panels represents a critical step toward a more precise, personalized approach to sepsis management to reduce sepsis-related morbidity and mortality. We advocate for further research and validation efforts to facilitate the clinical implementation of combined biomarker models, ultimately transforming sepsis care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersSepsisHumansPrognosis

Stichwörter der Autor:innen

BiomarkersInfectionLong-term outcomesSepsis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Physiology and Aging, University of Florida, Gainesville, FL, USA.
  • Department of Clinical Pharmacy and Pharmacology, University Medical Center of Groningen, University of Groningen, Groningen, the Netherlands.
  • Division of Gerontology, Geriatrics and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Anesthesia and Preoperative Care, School of Medicine, University of California, San Francisco, USA.
  • Department of Molecules and Materials, MESA+ Institute and TechMed Centre, University of Twente, the Netherlands.
  • Department of Clinical Chemistry and Laboratory Medicine, Medisch Spectrum Twente, Enschede, the Netherlands.

Förderung

  • NIGMS NIH HHS
  • National Institutes of Health
  • NIH National Institute of General Medical Sciences

Zitieren

APA

Ghaderpanah, R., van Beuningen, F., Lin, Y., Sadrian, S. H., Reijneveld, H. M., Krabbe, H., Jonkheijm, P., Bouma, H. R., & Mankowski, R. T. (2026). Sepsis as a complex syndrome: Are combined biomarkers the future of diagnosis and prognosis? Clinical perspective. Immunology Letters, 277, 107072. https://doi.org/10.1016/j.imlet.2025.107072

Vancouver

Ghaderpanah R, van Beuningen F, Lin Y, Sadrian SH, Reijneveld HM, Krabbe H, et al. Sepsis as a complex syndrome: Are combined biomarkers the future of diagnosis and prognosis? Clinical perspective. Immunology Letters. 2026;277:107072. doi:10.1016/j.imlet.2025.107072

BibTeX
@article{Ghaderpanah2026,
  author = {Ghaderpanah, R and van Beuningen, F and Lin, Y and Sadrian, S H and Reijneveld, H M and Krabbe, H and Jonkheijm, P and Bouma, H R and Mankowski, R T},
  title = {Sepsis as a complex syndrome: Are combined biomarkers the future of diagnosis and prognosis? Clinical perspective},
  journal = {Immunology Letters},
  year = {2026},
  volume = {277},
  pages = {107072},
  doi = {10.1016/j.imlet.2025.107072}
}
Kostenlos starten →